Stefan Toegel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9248527/publications.pdf

Version: 2024-02-01

58	2,378	218677	206112
papers	citations	26 h-index	48 g-index

59	59	59	3711
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	What is the Sugar Code?. ChemBioChem, 2022, 23, .	2.6	20
2	Recent Advances in Additive Manufacturing and 3D Bioprinting for Organs-On-A-Chip and Microphysiological Systems. Frontiers in Bioengineering and Biotechnology, 2022, 10, 837087.	4.1	15
3	Hydrolyzed Flavonoids from Cyrtosperma johnstonii with Superior Antioxidant, Antiproliferative, and Anti-Inflammatory Potential for Cancer Prevention. Molecules, 2022, 27, 3226.	3.8	4
4	The Dysregulated Galectin Network Activates NF-ÎºB to Induce Disease Markers and Matrix Degeneration in 3D Pellet Cultures of Osteoarthritic Chondrocytes. Calcified Tissue International, 2021, 108, 377-390.	3.1	6
5	Establishment of a human three-dimensional chip-based chondro-synovial coculture joint model for reciprocal cross talk studies in arthritis research. Lab on A Chip, 2021, 21, 4128-4143.	6.0	26
6	Nâ€Glycan profiling of chondrocytes and fibroblastâ€like synoviocytes: Towards functional glycomics in osteoarthritis. Proteomics - Clinical Applications, 2021, 15, e2000057.	1.6	8
7	Characterization of the Inducible and Slow-Releasing Hydrogen Sulfide and Persulfide Donor P*: Insights into Hydrogen Sulfide Signaling. Antioxidants, 2021, 10, 1049.	5.1	7
8	Galectin network in osteoarthritis: galectin-4 programs a pathogenic signature of gene and effector expression in human chondrocytes in vitro. Histochemistry and Cell Biology, 2021, , .	1.7	2
9	The genetic landscape of axonal neuropathies in the middle-aged and elderly. Neurology, 2020, 95, e3163-e3179.	1.1	19
10	Long-term impact of sagittal malalignment on hardware after posterior fixation of the thoracolumbar spine: a retrospective study. BMC Musculoskeletal Disorders, 2020, 21, 387.	1.9	2
11	Biological Regeneration of Articular Cartilage in an Early Stage of Compartmentalized Osteoarthritis: 12-Month Results. American Journal of Sports Medicine, 2020, 48, 1338-1346.	4.2	7
12	A 3-Dimensional In Vitro Model of Zonally Organized Extracellular Matrix. Cartilage, 2019, , 194760351986532.	2.7	3
13	Galectinsâ€1 and â€3 in Human Intervertebral Disc Degeneration: Nonâ€Uniform Distribution Profiles and Activation of Disease Markers Involving NFâ€ÎºB by Galectinâ€1. Journal of Orthopaedic Research, 2019, 37, 2204-2216.	2.3	8
14	Brazilin blocks catabolic processes in human osteoarthritic chondrocytes via inhibition of NFKB1/p50. Journal of Orthopaedic Research, 2018, 36, 2431-2438.	2.3	15
15	Galectin-8 induces functional disease markers in human osteoarthritis and cooperates with galectins-1 and -3. Cellular and Molecular Life Sciences, 2018, 75, 4187-4205.	5.4	46
16	Galectins: their network and roles in immunity/tumor growth control. Histochemistry and Cell Biology, 2017, 147, 239-256.	1.7	111
17	Osteoarthritis Biology. Learning Materials in Biosciences, 2017, , 189-204.	0.4	0
18	Galectin-3 Induces a Pro-degradative/inflammatory Gene Signature in Human Chondrocytes, Teaming Up with Galectin-1 in Osteoarthritis Pathogenesis. Scientific Reports, 2016, 6, 39112.	3.3	47

#	Article	IF	Citations
19	Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies. American Journal of Human Genetics, 2016, 99, 607-623.	6.2	47
20	Galectin-1 Couples Glycobiology to Inflammation in Osteoarthritis through the Activation of an NF-Î²Bâ€“Regulated Gene Network. Journal of Immunology, 2016, 196, 1910-1921.	0.8	77
21	Compounds from Caesalpinia sappan with anti-inflammatory properties in macrophages and chondrocytes. Food and Function, 2016, 7, 1671-1679.	4.6	44
22	Medical Plant Extracts for Treating Knee Osteoarthritis: a Snapshot of Recent Clinical Trials and Their Biological Background. Current Rheumatology Reports, 2015, 17, 54.	4.7	14
23	Inflammation Modulates RLIP76/RALBP1 Electrophile-Glutathione Conjugate Transporter and Housekeeping Genes in Human Blood-Brain Barrier Endothelial Cells. PLoS ONE, 2015, 10, e0139101.	2.5	15
24	Transport Rankings of Non-Steroidal Antiinflammatory Drugs across Blood-Brain Barrier In Vitro Models. PLoS ONE, 2014, 9, e86806.	2.5	73
25	Vascularization of primary and secondary ossification centres in the human growth plate. BMC Developmental Biology, 2014, 14, 36.	2.1	26
26	Human osteoarthritic knee cartilage: fingerprinting of adhesion/growth-regulatory galectins in vitro and in situ indicates differential upregulation in severe degeneration. Histochemistry and Cell Biology, 2014, 142, 373-388.	1.7	56
27	The need for transparency and good practices in the qPCR literature. Nature Methods, 2013, 10, 1063-1067.	19.0	251
28	Impact of heat treatment and spray drying on cellular properties and culturability of Bifidobacterium bifidum BB-12. Food Research International, 2013, 54, 93-101.	6.2	57
29	Glycophenotyping of osteoarthritic cartilage and chondrocytes by RT-qPCR, mass spectrometry, histochemistry with plant/human lectins and lectin localization with a glycoprotein. Arthritis Research and Therapy, 2013, 15, R147.	3.5	38
30	Isomeric analysis of oligomannosidic N-glycans and their dolichol-linked precursors. Glycobiology, 2012, 22, 389-399.	2.5	56
31	Caesalpinia sappan extract inhibits IL1Î²-mediated overexpression of matrix metalloproteinases in human chondrocytes. Genes and Nutrition, 2012, 7, 307-318.	2.5	38
32	Fluidized-bed drying as a feasible method for dehydration of Enterococcus faecium M74. Journal of Food Engineering, 2012, 111, 156-165.	5.2	33
33	Anti-inflammatory activity of an ethanolic Caesalpinia sappan extract in human chondrocytes and macrophages. Journal of Ethnopharmacology, 2011, 138, 364-372.	4.1	66
34	Radiopharmaceutical considerations on bone seeker uptake: should we learn from therapeutical targets of bisphosphonates?. Nuclear Medicine and Biology, 2011, 38, 617-618.	0.6	2
35	Phenotype-related differential Î±-2,6- or Î±-2,3-sialylation of glycoprotein N-glycans in human chondrocytes. Osteoarthritis and Cartilage, 2010, 18, 240-248.	1.3	45
36	IL-1Î² and TNF-Î± alter the glycophenotype of primary human chondrocytes in vitro. Carbohydrate Research, 2010, 345, 1389-1393.	2.3	41

#	Article	IF	Citations
37	MIQE prÃ©cis: Practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments. BMC Molecular Biology, 2010, 11, 74.	3.0	563
38	Bloodâ€“brain barrier cell line PBMEC/C1-2 possesses functionally active P-glycoprotein. Neuroscience Letters, 2010, 469, 224-228.	2.1	19
39	Preservation of aerial conidia and biomasses from entomopathogenic fungi Beauveria brongniartii and Metarhizium anisopliae during lyophilization. Journal of Invertebrate Pathology, 2010, 105, 16-23.	3.2	10
40	Reply to the comment on: comparison between chondroprotective effects of glucosamine, curcumin and diacerein in IL-1ÃŸ-stimulated C-28/I2 chondrocytes. Osteoarthritis and Cartilage, 2009, 17, 137.	1.3	0
41	Lectin binding patterns reflect the phenotypic status of in vitro chondrocyte models. In Vitro Cellular and Developmental Biology - Animal, 2009, 45, 351-360.	1.5	14
42	Growth surface-induced gene and protein expression patterns in Caco-2 cells. Acta Biomaterialia, 2008, 4, 1819-1826.	8.3	2
43	Comparison between chondroprotective effects of glucosamine, curcumin, and diacerein in IL-1Î²-stimulated C-28/I2 chondrocytes. Osteoarthritis and Cartilage, 2008, 16, 1205-1212.	1.3	51
44	What to consider in the development of new bone seekers: mechanistic and tracer-related aspects. Nuclear Medicine and Biology, 2008, 35, 817-824.	0.6	8
45	Preparation and pre-vivo evaluation of no-carrier-added, carrier-added and cross-complexed [68Ga]-EDTMP formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 406-412.	4.3	27
46	Validation of reference genes for qPCR studies on Caco-2 cell differentiation. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 1187-1192.	4.3	27
47	Innovations in Coating Technology. Recent Patents on Drug Delivery and Formulation, 2008, 2, 209-230.	2.1	40
48	An in vitro model for the comparative evaluation of bone seeking pharmaceuticals. ALTEX: Alternatives To Animal Experimentation, 2008, 25, 51-55.	1.5	6
49	Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP. Nuclear Medicine and Biology, 2007, 34, 391-397.	0.6	37
50	Selection of reliable reference genes for qPCR studies on chondroprotective action. BMC Molecular Biology, 2007, 8, 13.	3.0	53
51	Lectin binding studies on C-28/I2 and T/C-28a2 chondrocytes provide a basis for new tissue engineering and drug delivery perspectives in cartilage research. Journal of Controlled Release, 2007, 117, 121-129.	9.9	20
52	In vitro evaluation of no carrier added, carrier added and cross-complexed [90Y]-EDTMP provides evidence for a novel â€œforeign carrier theoryâ€• Nuclear Medicine and Biology, 2006, 33, 95-99.	0.6	9
53	Uptake of bone-seekers is solely associated with mineralisation! A study with 99mTc-MDP, 153Sm-EDTMP and 18F-fluoride on osteoblasts. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 491-494.	6.4	74
54	Binding studies of [18F]-fluoride and polyphosphonates radiolabelled with [99mTc], [111In], [153Sm] and [188Re] on bone compartments: Verification of the pre vivo model?. Bone, 2005, 37, 404-412.	2.9	20

#	Article	IF	Citations
55	Binding studies of [18F]-fluoride and polyphosphonates radiolabelled with [111In], [99mTc], [153Sm], and [188Re] on bone compartments: a new model for the pre vivo evaluation of bone seekers?. Bone, 2004, 34, 835-844.	2.9	16
56	Biological evaluation of 2â€²-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. Nuclear Medicine and Biology, 2004, 31, 291-295.	0.6	43
57	Radiosynthesis of 3-(2â€²-[18F]fluoro)-flumazenil ([18F]FFMZ). Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 1229-1240.	1.0	12
58	A Progress Report and Roadmap for Microphysiological Systems and Organ-On-A-Chip Technologies to Be More Predictive Models in Human (Knee) Osteoarthritis. Frontiers in Bioengineering and Biotechnology, 0, 10, .	4.1	2